Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacodynamic Responses: Different Types

Pharmacodynamic Responses: Different Types

Pharmacodynamics is the scientific study of a drug's biochemical or physiological influence on the body. It categorizes responses into continuous, discrete (or categorical), and time-to-event outcomes. Continuous responses yield numerical values within a certain range, such as blood pressure readings and blood glucose levels, gauging the efficacy of antihypertensive and antidiabetic drugs. Discrete responses can be binary, indicating whether a drug has an effect or not, or ordinal, exemplifying...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth.

Cell reports. Medicine·2026

Same author

Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth.

bioRxiv : the preprint server for biology·2026

Same author

Tebentafusp (IMCgp100), a first in class immune-mobilizing monoclonal T-cell receptors against cancer (ImmTAC) for HLA-A*02:01 positive uveal melanoma: Product review.

Human vaccines & immunotherapeutics·2026

Same author

Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.

Cancer·2026

Same author

Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma.

BMC cancer·2026

Same author

Reprogramming myeloid cells and restoring T cell fitness in checkpoint inhibitor resistant melanoma patients.

Biomarker research·2026

Search research articles

Related Experiment Videos

Atypical clinical response patterns to ipilimumab.

Blanca Ledezma¹, Sandra Binder, Omid Hamid

¹Oncology Department, University of California, Los Angeles, CA, USA. bledezmanp@gmail.com

Clinical Journal of Oncology Nursing

|August 4, 2011

Summary

Ipilimumab, a novel immunotherapy, offers new hope for advanced melanoma patients by modulating immune responses. Understanding its unique, delayed effects and managing immune-related adverse events is crucial for successful treatment outcomes.

Related Experiment Videos

Area of Science:

Oncology
Immunology
Pharmacology

Background:

Advanced melanoma presents limited therapeutic options and poor prognosis.
Understanding immune system-cancer interactions has spurred novel therapy development.
Ipilimumab targets cytotoxic T-lymphocyte antigen-4 (CTLA-4), a critical negative regulator of T-cell responses.

Observation:

Case studies of patients receiving ipilimumab in clinical trials were analyzed.
Patients exhibited diverse response patterns and immune-related adverse events (irAEs).
Successful management of irAEs was achieved in the presented cases.

Findings:

Atypical response patterns to ipilimumab reflect its mechanism, requiring time for immune-mediated antitumor response.
Apparent lesion enlargement may indicate T-cell infiltration, not necessarily disease progression.
Treatment responses can manifest over weeks to months, necessitating cautious continuation of therapy.

Implications:

Nurses play a vital role in managing ipilimumab therapy and its associated irAEs.
Early recognition and prompt management of irAEs are essential for favorable patient outcomes.
Clinicians should avoid premature termination of ipilimumab treatment, allowing time for therapeutic effects.